Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Clin Ther. 2017 Sep 19;39(11):2125–2134. doi: 10.1016/j.clinthera.2017.08.015

Table 4.

selected ongoing randomized phase III clinical trials investigating systemic therapy

Disease state Indication for treatment Intervention
Metastatic pancreatic cancer First-line metastatic therapy Napabucasin plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine
Metastatic pancreatic cancer First-line metastatic therapy PEGPH20 plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine
Locally advanced or metastatic pancreatic cancer First-line advanced therapy NC-6004 with Gemcitabine versus Gemcitabine alone
gBRCA-mutated metastatic pancreatic cancer whose disease has not progressed on first-line platinum-based chemotherapy Patients are on treatment with a first line platinum-based metastatic therapy without progression Maintenance Olaparib monotherapy versus Placebo
K-RAS wild-type locally advanced and metastatic pancreatic cancer Must have had no anti-tumor palliative chemotherapy or molecularly targeted therapy. Adjuvant therapy must have been more than 6 months prior. Nimotuzumab with Gemcitabine versus Placebo with Gemcitabine
Locally advanced and/or metastatic pancreas cancer that failed FOLFIRINOX Secord-line metastatic therapy Endo TAG-1 plus Gemcitabine versus Gemcitabine alone
Metastatic pancreatic cancer previously treated with gemcitabine Second-line metastatic therapy Glufosfamide versus Fluorouracil
Metastatic pancreatic cancer that has progressed during or following a first-line gemcitabine containing regimen Second-line metastatic therapy AM0010 with FOLFOX versus FOLFOX alone
Locally advanced or metastatic pancreatic cancer Second-line therapy for progressive advanced pancreatic cancer or progression after resection GV1001 with Gemcitabine/Capecitabine versus gemcitabine/Capecitabine alone